Platelets News and Research RSS Feed - Platelets News and Research

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

FDA approves use of Imbruvica to treat patients with chronic lymphocytic leukemia

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which is associated with poor responses to standard treatment for CLL. Imbruvica received a breakthrough therapy designation for this use. [More]
Scientists develop next-generation platelet bioreactor to generate functional human platelets

Scientists develop next-generation platelet bioreactor to generate functional human platelets

Scientists at Brigham and Women's Hospital (BWH) have developed a scalable, next-generation platelet bioreactor to generate fully functional human platelets in vitro. The work is a major biomedical advancement that will help address blood transfusion needs worldwide. [More]
Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel initiates Phase 3 clinical program for fostamatinib in patients with ITP

Rigel Pharmaceuticals, Inc. today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). [More]
Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Mitek Sports Medicine expands early intervention options for sports medicine physicians and patients

Mitek Sports Medicine, a leader in orthopaedics sports medicine and a part of the DePuy Synthes Companies of Johnson & Johnson, announced the launch of MONOVISC High Molecular Weight Hyaluronan, a single-injection treatment for knee pain related to osteoarthritis and the PEAK Platelet Rich Plasma (PRP) System, a new device that produces high quality PRP in only 2.5 minutes. [More]

Cerus enters into $30M growth capital credit facility with Oxford Finance

Cerus Corporation announced today that it has entered into a $30 million growth capital credit facility with Oxford Finance LLC. [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte’s ruxolitinib Phase III study for polycythemia vera achieves primary endpoint

Incyte Corporation (Nasdaq: INCY) today announced results from the RESPONSE trial, the first pivotal Phase III study evaluating a JAK1/JAK2 inhibitor for the treatment of polycythemia vera (PV). [More]
P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

P2Y12 and blood clotting: an interview with Dr. Jacobson, NIH

We already understand the many steps involved in blood clotting in great mechanistic detail. The process of blood vessels closing off in response to injury is necessary for preserving life, but blood platelets that are over-active, or activated inappropriately because of unstable plaque, can lead to heart attacks and strokes. [More]
Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior, Inc., today announced positive preliminary data from its Phase 2 trial of PRM-151, an anti-fibrotic immunotherapy, in patients with myelofibrosis which demonstrated biologic activity with improvements across clinically relevant measures, including bone marrow fibrosis, hemoglobin, platelets, spleen, and symptoms. [More]
PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

PGFX Patent Holdings acquires proprietary methods, devices, intellectual property from Orogen Biosciences

On Friday, April 18th PGFX Patent Holdings, operating as Heritage Biosciences, LLC made an asset acquisition of proprietary methods, devices and intellectual property from Orogen Biosciences, Inc. [More]
New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. [More]
Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Recycling patients' red blood cells during heart surgery better than banked blood transfusion

Patients whose own red blood cells are recycled and given back to them during heart surgery have healthier blood cells better able to carry oxygen where it is most needed compared to those who get transfusions of blood stored in a blood bank, according to results of a small study at Johns Hopkins. [More]
Researchers demonstrate possibility of using blood test to detect depression

Researchers demonstrate possibility of using blood test to detect depression

Researchers at the MedUni Vienna have demonstrated the possibility of using a blood test to detect depression. While blood tests for mental illnesses have until recently been regarded as impossible, a recent study clearly indicates that, in principle, depression can in fact be diagnosed in this way and this could become reality in the not too distant future. [More]

Cerus, Nipro partner to develop key component of INTERCEPT red cell disposable set

Cerus Corporation announced today that it has entered into a collaboration agreement with the Nipro Corporation's pharmaceutical division to develop technology to support commercial implementation of the INTERCEPT System for Red Blood Cells (RBCs). [More]
Study: Mutations could have major impact on treatment of human blood diseases

Study: Mutations could have major impact on treatment of human blood diseases

A study published today in Nature Genetics has revealed mutations that could have a major impact on the future diagnosis and treatment of many human diseases. [More]
Cook Medical launches Stemulate Pooled Human Platelet Lysate cell culture media supplement

Cook Medical launches Stemulate Pooled Human Platelet Lysate cell culture media supplement

Cook Medical will introduce its Stemulate Pooled Human Platelet Lysate cell culture media supplement at the 2014 International Society for Cellular Therapy meeting, April 23-26. [More]
Study shows how infection worsens damage caused by stroke

Study shows how infection worsens damage caused by stroke

Infection is bad news for all of us - but it can be really serious to people who have had a stroke. Evidence is mounting that infection makes things much worse after a stroke. [More]
Researcher develops synthetic hydrogel that promotes natural clotting, heals surgical wounds

Researcher develops synthetic hydrogel that promotes natural clotting, heals surgical wounds

Synthetic collagen invented at Rice University may help wounds heal by directing the natural clotting of blood. [More]
Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc. [More]
FDA allows CryoLife to begin PerClot clinical trial in the U.S.

FDA allows CryoLife to begin PerClot clinical trial in the U.S.

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has received approval of its Investigational Device Exemption (IDE) for PerClot from the United States Food and Drug Administration. [More]